The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Logiclinx Corporation
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Logiclinx Corporation, a non-promoter and US-based entity, disclosed the conversion of 30,62,754 warrants into equity shares of Telogica Limited, representing 6.40% of the total share capital (4.61% on a diluted basis). Before conversion, Logiclinx held 1,00,00,000 warrants (15.06% of diluted capital); after conversion it holds 30,62,754 equity shares plus 69,37,246 remaining warrants, keeping its overall diluted stake at 15.06%. The acquisition was executed via preferential allotment (warrant-to-equity conversion) on 29th October 2025. As a result of the conversion and simultaneous allotments to public shareholders, Telogica's total equity share capital increased from 3,37,73,032 shares to 4,78,35,786 shares.
This is a non-promoter investor increasing its actual equity stake by converting existing warrants, which dilutes other shareholders but does not introduce new promoter-related risk. The stock may see mild supply pressure if Logiclinx later sells, though their remaining warrants suggest continued long-term interest.